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Abstract
Background: To date, reliable and comprehensive health-related quality of life data for patients with relapsed or
refractory B-precursor acute lymphoblastic leukemia (ALL) have not been collected in clinical trials of the disease,
and no utility studies have been published. The purpose of this study was to define and validate health states
experienced by adults with relapsed/refractory B-precursor ALL, and to assign utility values to these health states
using time-trade off methodology.
Methods: This study was conducted in the UK in three phases. In the first phase, five health state descriptions were
developed based on a recent clinical trial. The second phase validated the health state descriptions with clinicians
and patients with experience of relapsed/refractory B-precursor ALL. The third phase involved prospective health
state valuation using time-trade off methodology in a sample of the general public. The study was approved by the
UK National Health Service Research Ethics Committee.
Results: In total, 123 participants were recruited and included in the final analysis; all participants gave written,
informed consent. Complete remission was the most preferred health state (mean utility [SEM], 0.86 [0.01]), followed
by complete remission with partial hematological recovery (with minimal risk of bleeding or developing infection)
(0.75 [0.02]); aplastic bone marrow (0.59 [0.02]); partial remission (0.50 [0.03]); and progressive disease (0.30 [0.04]).
Conclusions: This is the first study to report utility values for health states associated with relapsed/refractory
B-precursor ALL. It was designed and conducted to align with NICE guidance on alternative methods for
generating health state utility values when EQ-5D data are either unavailable or inappropriate. These utilities
can be applied in future cost-effectiveness analyses of treatment for relapsed/refractory B-precursor ALL.
Keywords: Leukemia, Lymphoblastic, Acute, Precursor B-cell, Health-related quality of life, Stated preference,
Utility value
Background
Acute lymphoblastic leukemia (ALL) is a rare and ag-
gressive disease; in 2011, there were approximately 650
new cases of ALL in the UK, representing only 0.2 % of
all new cancer cases [1]. Although first-line treatments
for B-precursor ALL have improved survival rates, a
considerable proportion of patients are refractory to
treatment or experience relapse [2–5]. Adults with re-
lapsed or refractory B-precursor ALL have a very poor
prognosis; the main aim of treatment is to achieve a durable
remission without compromising health-related quality of
life (HRQL) [2–5]. However, the HRQL of adults with re-
lapsed or refractory B-precursor ALL, including the impact
of their treatment, is not well understood. This is likely due
to the rarity of the disease.
In many countries, the decision to approve novel therap-
ies is informed by calculation of the cost per quality ad-
justed life-year, which requires utility data to quantitatively
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compare health states alongside survival [6, 7]. Gener-
ally, HTA agencies prefer utility data derived directly
from patients in a clinical trial, using the EQ-5D [6–8].
The EQ-5D is a standardized measure of health status,
and is applicable to a wide range of health conditions
and treatments [9]. To date, neither EQ-5D nor other
HRQL data have been collected in clinical trials of B-
precursor ALL.
When EQ-5D data are unavailable, alternative meth-
odologies for generating utility values, such as the use of
preference elicitation, can be used. Preference elicitation
may also be particularly appropriate for determining
utility values for rare diseases such as B-precursor ALL,
where generating data from clinical trials can be challen-
ging due to trial sample size or patient fitness and ques-
tionnaire burden. Of the techniques that can be used for
preference elicitation, time trade-off (TTO) is the preferred
method according to the guidelines of the National Insti-
tute for Health and Care Excellence (NICE) in the UK [8].
Considering the small patient population for B-precursor
ALL and the lack of HRQL data in the literature, a utility
study was designed in line with acceptable evidence in the
NICE hierarchy. The purpose of this study was to define
and validate health states experienced by adults with
relapsed or refractory B-precursor ALL in the UK and
to assign utility values to these health states, from the




This study was conducted in the UK between January
2013 and July 2014 (Fig. 1). The study was undertaken
in three phases, described below: development of the
health state descriptions, validation, and valuation. Valu-
ation itself consisted of a two-part process: a pilot and a
main preference elicitation study; the results from the
main elicitation study only are presented here. The study
design and all materials were reviewed and approved
by the UK National Health Service Research Ethics
Committee (reference 13/NW/0683).
Development of the health state descriptions
Five health state descriptions were developed to describe
the burden of B-precursor ALL and response to treat-
ment: complete remission (CR), complete remission with
partial hematological recovery (with minimal risk of
bleeding or developing infection: platelets > 50,000/μl,
and absolute neutrophil count (ANC) > 500/μl) (CRh),
aplastic bone marrow (aBM), partial remission (PR), and
progressive disease (PD). Development of health state
descriptions was initially based on definitions from a
single-arm Phase 2 clinical trial in 189 patients with re-
lapsed or refractory B-precursor ALL, which defined all
of the above as potential treatment outcomes and de-
fined attainment of CR or CRh as the primary endpoint,
(NCT01466179; [10]) and a literature review, which con-
firmed that there is no comprehensive HRQL informa-
tion available for this patient population.
Each health state description included elements of
symptoms and aspects of physical, functional, emotional,
and social well-being, in line with the domains used in the
FACT-Leu HRQL instrument [11]. The range for severity
of symptoms depended on the health state being de-
scribed. The structure and length of the descriptions were
compared against health state descriptions published
Fig. 1 Overview of study procedures
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elsewhere in other cancers, such as chronic lymphocytic
leukemia (CLL) [6], advanced melanoma [12], metastatic
breast cancer [13], and chronic myeloid leukemia (CML)
[14]. Adverse events that patients may experience during
treatment were not included in the health state descrip-
tions in order to keep the health state utility values inde-
pendent of the treatment received. Terminology around
cancer or leukemia was not included in the health state
descriptions based on the conclusions of a study which
found that the inclusion of a cancer label in health state
descriptions negatively affects health state values [15].
A clinician experienced in the treatment of B-precursor
ALL was then interviewed about the proposed health state
definitions and based on this interview, the descriptions
were amended to include the effect of hospital visits and
the impact on a patient’s social life.
Validation of the health state descriptions
To ensure their clinical accuracy and completeness, the
five health state descriptions were next validated by two
consultant hematologists and two clinical nurse special-
ists who had treated patients with relapsed or refractory
B-precursor ALL in the previous 36 months, and three
patients receiving treatment for B-precursor ALL.
The clinicians and nurses were provided with the health
state descriptions and asked to give written feedback via a
web-based structured questionnaire on whether the signs
or symptoms of adult B-precursor ALL were correctly
captured and whether the five health states descriptions
based on treatment response were accurate. Comments
from the health professionals were reviewed and summa-
rized; majority decisions were taken for any contradictory
comments between the health professionals. Based on the
feedback, minor amendments were made to the descrip-
tions; the most important aspects added included the pa-
tient’s typical emotional state and the frequency of
hospital visits. It was concluded that including additional
emotional aspects of the disease would aid comprehension
of the health states, as some of the physical descriptions of
the disease were relatively abstract (e.g., blood counts).
Individual phone interviews were conducted with all
the reviewers to confirm that proposed changes were
appropriate.
The amended health state descriptions were then vali-
dated by three patients with B-precursor ALL. The pa-
tients were interviewed individually and face-to-face,
using a semi-structured questionnaire, by an experienced
NHS-based qualitative researcher with extensive experi-
ence of interviewing patients. The patients were asked to
comment on the comprehensibility and face validity of
the health state descriptions. The researcher asked the
patients specifically about the impact of B-precursor
ALL on their lives, the symptoms they experienced, and
how these affected their personal and social lives. The
patients also provided feedback on how clear the health
state descriptions were, whether they reflected experi-
ences patients may have, and whether any aspect was
missing. The discussions were recorded and transcribed,
and the transcripts analyzed by researchers to identify
any consensus on the completeness and the compre-
hensiveness of the health state descriptions, and any
supplementary descriptive items needed. Overall, the
patients agreed with the health state descriptions, in-
cluding the emotional aspects, and only minor amend-
ments were made.
Valuation of the health states
Health states were valued using a pilot and a main pref-
erence elicitation study, using TTO methods, with mem-
bers of the general public in the UK.
Participants were recruited by a third-party vendor
specializing in research with members of the public. Par-
ticipants were recruited from London for the pilot study,
and from London, Newcastle, and Edinburgh for the main
study. Potential participants were screened based on age,
sex, ethnicity, and socio-economic status to achieve a rep-
resentative sample of the general UK population based on
data from the Office of National Statistics 2011 Census for
England and Wales [16].
Participants had to be at least 18 years of age at the
time of the interview, able to understand the study pro-
cedures as judged by the investigator, and able to write
and speak English. All participants were required to
attend the interview in person. Exclusion criteria were
severe cognitive impairment, hearing difficulty, visual
impairment, or psychopathology as judged by the inves-
tigator. All participants provided informed consent and
received compensation (fair market value) for their time
and travel.
A pilot study was conducted with a small but repre-
sentative sample of the general population in the UK
(n = 28). The main aims were to confirm the utility
elicitation methodology, ensure the health state de-
scriptions were clear and easy to understand, and en-
sure participants are able to complete the interview in
the time allotted.
Based on analysis of the pilot results, the following
changes to the TTO exercise were made for the main
part of the preference elicitation study:
 The health states underwent minor revisions to
reduce the length and make differences between the
states more clear.
 A ‘prior to treatment’ statement was designed to
introduce the participants to what it would be like
to have B-precursor ALL; this description was the
same for each post-treatment health state. The
amended health state descriptions were validated
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with one consultant hematologist and one specialist
nurse prior to the main part of the preference elicit-
ation study.
 Small simplifications to questionnaires were made;
participants would be able to indicate their
preference for a health state by circling it, whereas
in the pilot study participants used ticks and crosses
to indicate a preference as suggested in the MVH
protocol (MVH Group, [20]).
The final health states used in the main part of the
preference elicitation study are presented in Additional
file 1.
In the main part of the preference elicitation study, par-
ticipants completed the TTO questionnaires in group ses-
sions comprising 15–17 individuals (8 sessions). Thus, four
different versions of the questionnaire were generated, each
containing all five of the health state descriptions, but pre-
sented in a unique order. Randomization was done by a
statistical algorithm. During the exercise, health states were
referred to as A, B, C, D and E, so as not to influence par-
ticipant responses (see Additional file 1).
Participants in each session were provided with written
and verbal descriptions of the exercise, and instructions
on how to complete the TTO questionnaire, which was
demonstrated with an example. After completing standard
demographic questions, participants were asked to rate
their own health on the day using the EQ-5D. The partici-
pants then rated the health state descriptions for relapsed/
refractory B-precursor ALL.
Preference elicitation
The valuation exercise in both the pilot and main study
was accomplished through self-completion of a paper-
based TTO questionnaire in a moderated group session,
based on the MVH protocol modelling of valuation
tariffs [17] (see Additional file 2). Trained moderators
were available to answer participants’ questions through-
out the exercise.
For each health state, participants were asked to state
whether they would prefer to live in the health state de-
scribed for 10 years, followed by death, or whether they
would trade any of the 10 years to live a shorter time in
full health. Participants completed a table in which they
could choose between “perfect health” or a particular
health state, where the health state lasted for 10 years
and the duration of perfect health was a progressively
shorter period in each row, ending at zero (i.e., death).
The point at which the participant could not choose be-
tween perfect health and the health state was considered
the point of indifference and used to calculate the utility
score. If participants did not reach this point of indiffer-
ence, the first time a participant choose perfect health
was used in the calculations for the utility score.
In accordance with the MVH protocol, if participants
preferred immediate death to living in a health state for
10 years, they were asked to complete another table in
which they were asked to choose between immediate death
and combinations of time in the health state followed by
perfect health (for a combined duration of 10 years). In-
creasing periods of time in the health state (with decreas-
ing periods of time in perfect health) were presented to
find the point of indifference among these choices.
Although patients with relapsed or refractory B-
precursor ALL generally have a much shorter life span,
the 10-year time trade-off was used to align with the
MVH York protocol.
Statistical analysis
Quantitative analysis that generated descriptive statistics
(mean, standard deviation, and frequency) was used to
summarize the utility values and characterize the sample
in terms of socio-demographic and other characteristics.
The study responses were also analyzed descriptively
(mean and standard deviation) to determine average
time to completion and the difference in value between
health states. The study was not powered to test for sta-
tistically significant differences between subgroups or
between the study population and previously published
data from the UK general population.
The health states were scored as follows:
 For states better than death, the numbers of years
of perfect health that respondents would trade for
10 years in each health state were converted to a
relative utility value using a simple fraction:
(10 – t)/10, where t was the amount of time in years
that was traded [17].
 For states worse than death, scores were
converted to a relative utility value using the
transformation: t’ = − t/(10–t), where t is the
amount of time spent in full health [17]. These
values were then truncated at −1, which replaced
all values below −1. The mean utility was
calculated using the truncated values.
Results
In total, 123 participants (55 from London, 25 from
Edinburgh, and 43 from Newcastle) were recruited to
the main study and included in the final analysis. The
demographic profile of the study population was similar
to the 2011 census data for sex, age, ethnicity, economic
activity, and marital status (Table 1). The household size,
household income, and education level of the study
population were slightly higher than those of the UK
general population. Tests for statistically significant dif-
ferences in demographics between centers, or between
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this study and the UK general population, were not
conducted.
The completion rate for the questionnaire was 100 %;
participants took an average of 25 min (range: 9–53
min) to complete the questionnaire. All participants in-
dicated that they understood the health state descrip-
tions and were able to score them using the TTO
questionnaire, although one participant noted that it was
difficult to imagine the cumulative impact of the symp-
toms described.
The mean EQ-5D score for participants was 0.91 (SD
0.17), which is slightly higher than previously published
EQ-5D scores for the UK general population: 0.86 (SD
0.23; [18] and 0.868 (range:−0.594 to 1; [19]). Tests for
statistically significant differences in EQ-5D scores be-
tween this study and the UK general population were
not conducted.
Complete remission and complete remission with par-
tial hematological recovery (with minimal risk of bleed-
ing or developing infection) were associated with the
highest mean utility values (SEM): 0.86 (0.01) and 0.75
(0.02), respectively, indicating the lowest HRQL burden
(Table 2). The progressive disease state had the lowest
values (0.30 [0.04]), indicating the highest burden. Aplastic
bone marrow and partial remission had mean values of
0.59 (0.02) and 0.50 (0.03), respectively.
Nine participants scored progressive disease as worse
than death; two participants valued partial remission as
worse than death; and one participant considered aplas-
tic bone marrow to be worse than death.
Discussion
To our knowledge, this is the first study to generate util-
ity values for health states related to adult relapsed or
refractory B-precursor ALL. As expected, preferences for
treatment response states (i.e., complete remission or
complete remission with partial hematological recovery)
were substantially higher than for progressive disease,
and decreased logically with increasing disease severity.
Previous utility studies of advanced or rare cancers have
generally demonstrated that health states for treatment
response and stable disease are preferred to progressive
disease [6, 12, 14], as these states are associated with a
lower burden on patients. These results indicate that the
general public were able to differentiate and value clin-
ical health states for patients with relapsed or refractory
Table 1 Sex, age, ethnicity, and economic activity of the study






M:F 62 (50.4):61 (49.4) 49: 51
Age group (years)
18–29 23 (18.7) 20.6
30–44 34 (27.6) 26.1
45–59 34 (27.6) 24.8
60–74 27 (22.0) 18.7
75+ 5 (4.1) 9.8
Ethnicity
White (British or other white) 108 (87.8) 87.1
Non-white 15 (12.2) 12.9
Economic activity
Full-time work (30+ hours) 60 (48.8) 37.4
Part-time work 11 (8.9) 12.6
Self-employed 8 (6.5) 8.5
Full-time education 7 (5.7) 3.5
Retired 22 (17.9) 22.1
Looking after home 5 (4.1) 3.3
Long-term illness/disabled 2 (1.6) 3.4
Unemployed/seeking work 4 (3.3) 8.3
Other 4 (3.2) 1.2
Marital status
Single 42 (34.1) 34.7
Married/Civil partnership 56 (45.5) 46.7
Divorced/Separated/Legally dissolved 22 (17.9) 11.5
Widowed 3 (2.4) 7.0
Household size
1 27 (22.0) 30.6
2 32 (26.0) 34.1
3–4 24 (39.0) 28.5
5–6 16 (13.0) 6.2
Household income (£)
0–19,999 26 (23.6) 49.9
20,000–29.999 19 (17.3) 22.7
30,000–49,999 42 (38.2) 18.6
50,000–99,999 20 (18.2) 6.7
100,000 or more 3 (2.7) 2.2
Preferred not to answer 13 (10.5) NA
Education level
No formal qualifications 11 (8.9) 23.2
Apprenticeships 6 (4.9) 3.3
Table 1 Sex, age, ethnicity, and economic activity of the study
sample (n = 123) (Continued)
High school education 72 (58.5) 41.4
University degree or professional
qualification
31 (25.2) 27.0
Other 3 (2.4) 5.1
Source: [16]
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B-precursor ALL. The utilities generated can therefore
be used in future cost-effective evaluations of treatments
for relapsed or refractory B-precursor ALL in adults.
The study implemented methodology to align with
NICE guidance on alternative methods for generating
health state utility values when EQ-5D data are either
unavailable or inappropriate. After confirming the
lack of utility values for adult relapsed or refractory
B-precursor ALL through a systematic search of the
literature, we developed and validated five health
states for the disease. The validation process incorpo-
rated interviews with consultant hematologists, clin-
ical nurses and three patients with B-precursor ALL,
despite the rarity of the disease. The descriptions
therefore captured important elements of the patient
experience, ensuring strong content and face validity.
Finally, we used TTO during the valuation phase and
followed standard procedures for the exercise and the
analysis of the results [17, 20]. Notably, utility values
for other types of leukemia have been elicited using
similar methodology [21, 22]. Although these studies
were in chronic leukemia (CLL and CML), their use
of preference elicitation highlights the lack of HRQL
data for leukemia and supports our approach gener-
ally. Overall, this methodology meets the standards
set out in NICE guidance, and is a key strength of
the study.
NICE have stated that health state utility values for
participants should be comparable with values from
the UK general population, to ensure the face validity
of the health state valuations [7, 8]. Although the
utility value for complete remission in this study was
the same as reported for the average of the UK gen-
eral population (0.86), it should be noted that the
self-rated utility of the study sample was higher
(0.91). A slightly healthier sample is generally ex-
pected in this type of study, where participants are
required to attend a study site and the rank order of
the study health states are logical. The health state
descriptors do not take into account comorbidities
present in the UK general population, which would
potentially reduce valuations. Further, the health state
descriptions must be relatively short for this type of
study, and may therefore have excluded elements that
could potentially have influenced valuations.
Utility values below −1 were truncated in the base case
analysis, but several alternative methods for handling
these values exist and the best method is subject to de-
bate [23–26]. In theory, there is no lower bound on the
utility values for states worse than death. Lamers and
colleagues consider that median values should be used,
but NICE guidance states that health state valuation for
economic evaluation to inform decision-making has
been based mainly on mean values to date [25, 27].
Mean values give all individuals a weighting that is pro-
portional to them, which is important in the valuation of
health states because the values should reflect the prefer-
ences of the whole population, and not consider some
valuations to be more accurate than others.
The sample was generally representative of the UK
population. A higher proportion of respondents had an-
nual incomes of £50,000–99,999 than in the 2011 census
(18.7 versus 6.7 %) and a lower proportion had no for-
mal qualifications (8.9 versus 23.2 %). This may be re-
lated to the greater number of participants from London
(n = 55), where living costs are high. However, these
demographic variables have not been shown to be reli-
able predictors of health state utilities and are not ex-
pected to have had a significant effect on the valuation
of the health state descriptions [17]. Importantly, the age
distribution in the study sample closely matches that of
the UK population, with the exception of elderly partici-
pants, who are slightly underrepresented. This is perhaps
due to the face-to-face methodology; elderly people may
have had more difficulty in attending the study site. Age
has been shown to influence valuations of health [17];
adults over 60 years old tend to regard many health
states as being much worse than the rest of the popula-
tion. The MVH Group found that some of this differ-
ence may be due to older people believing they would
never regain full health after severe disease states; how-
ever some of the difference was also genuine. As such,
including a higher proportion of elderly people may have
slightly lowered our utility values.
Conclusions
This large study used a methodology in line with NICE
guidance to elicit utility values for health states in re-
lapsed or refractory adult B-precursor ALL from the UK
general population. The utility values generated can be
applied in cost–utility analyses of treatments for this
condition.
Table 2 Mean TTO utility values for disease-related health states
in B-precursor ALL (n = 123)











0.75 0.02 0.45 0.038
Aplastic bone marrow 0.59 0.02 0.29 0.034
Partial remission 0.50 0.03 0.20 0.032
Progressive disease 0.30 0.04 – –
Abbreviations: SEM standard error of the mean, TTO time trade-off
aHealth state utility values range from 0 to 1; 0 is death and 1 is perfect health
bProgressive disease was the anchoring health state for calculation
of increments
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